RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models

about

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models

Item

http://www.wikidata.org/entity/Q57493689

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@en

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@nl

type

Item

label

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@en

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@nl

prefLabel

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@en

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@nl

P1476

RN765C, a low affinity EGFR an ...... preclinical solid tumor models

@en

P2093

Arvind Rajpal

http://www.w3.org/2001/XMLSchema#string

David L Shelton

http://www.w3.org/2001/XMLSchema#string

Kevin C Lindquist

http://www.w3.org/2001/XMLSchema#string

Marjorie Bateman

http://www.w3.org/2001/XMLSchema#string

Melinda Au

http://www.w3.org/2001/XMLSchema#string

Meritxell Galindo Casas

http://www.w3.org/2001/XMLSchema#string

Oi Kwan Wong

http://www.w3.org/2001/XMLSchema#string

Pavel Strop

http://www.w3.org/2001/XMLSchema#string

Shu-Hui Liu

http://www.w3.org/2001/XMLSchema#string

Thomas-Toan Tran

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

The quest to overcome resistance to EGFR-targeted therapies in cancer.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Phosphopantetheinyl Transferases.

Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.

Targeting the epidermal growth factor receptor in solid tumors: focus on safety.

Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.

P304

33446-33458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.26002

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30323890

http://www.w3.org/2001/XMLSchema#string

P932

6173368

http://www.w3.org/2001/XMLSchema#string